Cardiovascular safety assay

Details Cardiovascular safety assay Cardiovascular safety assay

2006-11-06

2010-10-26

Prouty, Rebecca E. (Department: 1657)

Chemistry: analytical and immunological testing

Biospecific ligand binding assay

Utilizing isolate of tissue or organ as binding agent

C435S007100, C435S007800, C435S029000, C436S501000

Reexamination Certificate

active

07820453

ABSTRACT:
The present invention provides assays and kits for the screening of test compounds for their capability to induce cardiotoxicity in a subject. Said assays and kits are based on the finding that the interaction of astemizole with the HERG potassium channel can be exploited to predict cardiotoxicity of compounds during the development of new therapeutics and other agents.

REFERENCES:
patent: 4568649 (1986-02-01), Bertoglio-Matte
patent: 0070079 (2000-11-01), None
patent: WO 02/42735 (2002-05-01), None
Wells. Additivity of Mutational Effects in Proteins; Biochemistry, vol. 29, No. 37 (1990) pp. 8509-8517.
Seffernick et al. Melamine Deaminase and Atrazine Chlorohydrolase: 98 Percent Identical but Functionally Different; Journal of Bacteriology, vol. 183, No. 8 (2001) pp. 2405-2410.
Chiu et al. Validation of A [H3]Astemizolebinding Assay in HEK293 Cells Expressing Herg K+ Channels; Journal of Pharmacological Sciences, vol. 95 (2004) pp. 311-319.
Zhou et al. Block of Herg Potassium Channels by the Antihistamine Astemizole and Its Metabolites Desmethylastemizole and Norastemizole; Journal of Cardiovascular Electrophysiology, vol. 10, No. 6 (1999) pp. 836-843.
Taglialatela, M. et al. “Cardiac Ion Channels and Antihistamines: Possible Mechanisms of Cardiotoxicity”. Clinical and Experimental Allergy, vol. 29, No. Suppl. 3, Jul. 1999, pp. 182-189. XP002198163.
Yap, Y.G. et al. “Arrhythmogenic Mechanisms of Non-Sedating Antihistamines”. Clinical and Experimental Allergy. vol. 29, No. Suppl. 3, Jul. 1999, pp. 174-181. XP002198165.
Drici, M.D. et al. “Cardiac K+ channels and Drug-Acquired Long QT Syndrome”. Therapie. New England 2000 vol. 55, No. 1. XP002198169.
Altschul, Stephen F. et al. “Gapped Blast and PSI-Blast: A New Generation of Protein Database Search Programs”. Nucleic Acids Research, 1997, vol. 25, No. 17, pp. 3389-3402, Oxford University Press, University Park, PA., USA.
Dall'Asta, Valeria et al. “Membrane Potential Changes Visualized in Complete Growth Media through Confocal Laser Scanning Microscopy of bis-Oxonol-Loaded Cells”. Experimental Cell Research, 231, 1997, pp. 260-268, Parma, Italy.
Chadwick, Christopher C. et al. “Identification of a Specific Radioligand for the Cardiac Rapidly Activating Delayed Rectifer K+ Channel”. Circulation Research, Mar. 1993, vol. 72, No. 3, pp. 707-714, Alnwick Reseach Center (UK).
Claycomb, William C. et al. “HL-1 Cells: A Cardiac Muscle Cell Line that Contracts and Retains Phenotypic Characteristics of the Adult Cardiomyocyte”. Proceedings of the National Academy of Sciences of the United States, vol. 95, No. 6, Mar. 17, 1998, pp. 2979-2984. XP002198161.
Netzer, Rainer et al. “Screening Lead Compounds for QT Interval Prolongation”. Drug Discovery Today, vol. 6, No. 2, 2001, pp. 78-84. XP002198162.
Finlayson, Keith et al. “3HDofetilide Binding to HERG Transfected Membranes: A Potential High Throughput Prelinical Screen”. European Journal of Pharmacology, vol. 430, No. 1, 2001, pp. 147-148. XP002198164.
Bischoff, Ulrike et al. “Effects of Fluoroquinolones on HERG Currents”. European Journal of Pharmacology. vol. 406, No. 3, 2000, pp. 341-343. XP002198166.
Jones, Stephen E. et al. Inhibition of the Rapid Component of the Delayed-Rectifier K+ Current by Therapeutic Concentrations of the Antispasmodic Agent Terodiline. vol. 125, No. 6, Nov. 1998, pp. 1138-1143, XP002198167.
Rampe, David et al. “The Antipsychotic Agent Sertindole is a High Affinity Antagonist of the Human Cardiac Potassium Channel HERG”. Journal of Pharmacology and Experimental Therapeutics, vol. 286, No. 2, Aug. 1998, pp. 788-793. XP002198168.
In the U.S. Patent and Trademark Office, Non-Final Office Action in re: U.S. Appl. No. 10/483,617 dated Jan. 12, 2006, 15 pages.
In the U.S. Patent and Trademark Office, Final Office Action in re: U.S. Appl. No. 10/483,617 dated May 5, 2006, 11 pages.
In the U.S. Patent and Trademark Office, Advisory Action in re: U.S. Appl. No. 10/483,617 dated Sep. 7, 2006, 3 pages.
Bakibaev et al., Methods for the Synthesis of Nitrogen-Containing Heterocycles using Ureas and Related Compounds, Russian Chemical Reviews (1998), 67(4):333-352, abstract only.
Dascal N., The Use of Xenopus Oocytes for The Study of Ion Channels, Crit.Rev.Biochem. (1987), 22(4):317-387.
Gerlt et al., Can Sequence Determine Function?, Genome Biology (2000), 1(5).
Haverkamp et al., The Potential for QT Prolongation and Pro-Arrhythmia by Non-Anti-Arrhythmic Drugs: Clinical and Regulatory Implications Report on a Policy Conference of the European Society of Cardiology, Cardiovascular Research (2000), 47:219-233.
Thijssen et al., Synthesis of 3H and 14C-Labeled Astemizole (R43512); Journal of Labeled Compounds and Radiopharmaceuticals (1983), 20(7):861-868.
Tsien et al., FRET for Studying Intracellular Signalling, Trends Cell Biology (1993), 3:242-245.
Zhou et al., Properties of HERG Channels Stably Expresses in HEK 293 Cells Studied at Physiological Temperature, Biophysical Journal (1998), 74:230-241.
International Search Report dated Dec. 2, 2002 for related International Application No. PCT/EP02/07364.

Affiliated with

Also associated with

Rating

Cardiovascular safety assay does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cardiovascular safety assay, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cardiovascular safety assay will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4202519